China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of Hepatitis C (HCV) patients. The key driver of the Chinese HCV market is the increase in the drug-treated population due to the introduction of novel HCV-specific therapies that will be combined in highly effective, all-oral IFN-free regimens. Combined with increasing access to medical care and a burgeoning middle class with growing economic clout, these factors promise fast growth and significant opportunity for multinational pharmaceutical companies.
Market Covered: China
Primary research: The analysis of physician insight into current and future HCV medical practice presented in this report is based on face-to-face interviews of 50 hepatologists and gastroenterologists in China.
Patient flow model: Our quantitative analysis estimates the total size of the viremic HCV population and fragments it into subpopulations based on patients’ viremic status, HCV genotype, and prior treatment history. Ten-year annual epidemiology forecasts through 2023.